LinkBIO Co.Ltd,
- Biotech or pharma, therapeutic R&D
- Diagnostics
LinkBIO Co., Ltd. is a biotech startup leading the development of bispecific DNA aptamer therapeutics. Our core innovation is MACE®-SELEX, a proprietary aptamer screening platform co-patented with the University of Tokyo, enabling the creation of highly functional aptamers, such as targeted protein degradation with induced proximity.
We are the first globally to advance bispecific aptamer drugs for rare hematologic diseases, aiming to provide breakthrough treatments where current options are limited or nonexistent.
In addition to therapeutic pipelines, LinkBio is actively working to broaden the application and awareness of nucleic acid aptamers across the fields of diagnostics, biomedical research, and biotechnology.
Our business activities include:
- Collaborative and contract-based R&D projects, particularly the co-development of 2 ongoing therapeutic pipelines
- Licensing opportunities for MACE®-SELEX
- Aptamer screening services
- Sales of high-affinity, target-specific aptamer binders
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}